New insights into natural killer cells of anti-cancer activity


Oncolytics Biotech® Inc. today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology. The article, titled “Oncolytic virus treatment differentially affects CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity,” was published in collaboration with researchers from several institutions. prestigious institutions, including the University of Leeds Medical School and the Institute of Cancer Research, London. A link to the document can be found by clicking here.

The article describes in vitro studies evaluating the effects of pelareorep on Natural Killer (NK) cells as well as analyzes of blood samples from patients with colorectal liver metastases taken before and after treatment with pelareorep. The results showed that pelareorep treatment resulted in the activation of NK cells, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity. The beneficial effects of pelareorep have been observed both in patient samples and in vitro and were mediated by interferon type 1 (IFN-1) signaling, a key pathway involved in immunoregulation and recognition tumor cells.

“These important results demonstrate both the innate and adaptive immunological mechanism of action of pelareorep, and we are delighted to have published them in such a prestigious, peer-reviewed journal,” said Dr. Matt Coffey, President and Chief of the management of Oncolytics Biotech and co-author of the article. “Reviewing these results, along with previous clinical data demonstrating the ability of pelareorep to activate T cells while promoting their infiltration into tumors, we find that pelareorep delivers a robust and coordinated anti-cancer immune response, driven by both innate and adaptive immune systems. Going forward, we will continue to leverage the immunotherapeutic effects of pelareorep as we pursue its development as an enabling technology for a wide range of immunotherapeutic agents in breast cancer and other oncology indications with unmet needs. satisfied high.

The patient samples evaluated in the publication were from a completed clinical window of opportunity study evaluating pelareorep in colorectal cancer patients with liver metastases. Patients received between one and five doses of pelareorep prior to scheduled surgery to resect metastases. Blood samples were taken before and at several time points after treatment with pelareorep. Additional details about the trial, as well as previously reported results, are available in previous peer-reviewed publications.


Comments are closed.